

Hak-Kim Chan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5771827/publications.pdf>

Version: 2024-02-01

496
papers

20,433
citations

10956

71
h-index

26548

107
g-index

512
all docs

512
docs citations

512
times ranked

13685
citing authors

#	ARTICLE	IF	CITATIONS
1	Production methods for nanodrug particles using the bottom-up approach. <i>Advanced Drug Delivery Reviews</i> , 2011, 63, 406-416.	6.6	351
2	Nano spray drying: A novel method for preparing protein nanoparticles for protein therapy. <i>International Journal of Pharmaceutics</i> , 2011, 403, 192-200.	2.6	333
3	Recommendations for the standardisation of oxytocin nasal administration and guidelines for its reporting in human research. <i>Psychoneuroendocrinology</i> , 2013, 38, 612-625.	1.3	313
4	Predictive Markers of Asthma Exacerbation during Stepwise Dose Reduction of Inhaled Corticosteroids. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2001, 163, 406-412.	2.5	302
5	Nanodrugs: pharmacokinetics and safety. <i>International Journal of Nanomedicine</i> , 2014, 9, 1025.	3.3	274
6	Micronization by Rapid Expansion of Supercritical Solutions to Enhance the Dissolution Rates of Poorly Water-Soluble Pharmaceuticals. <i>Industrial & Engineering Chemistry Research</i> , 2000, 39, 4794-4802.	1.8	236
7	Use of solid corrugated particles to enhance powder aerosol performance. <i>Pharmaceutical Research</i> , 2001, 18, 1570-1577.	1.7	209
8	Inhaled formulations and pulmonary drug delivery systems for respiratory infections. <i>Advanced Drug Delivery Reviews</i> , 2015, 85, 83-99.	6.6	198
9	How Much Particle Surface Corrugation Is Sufficient to Improve Aerosol Performance of Powders?. <i>Pharmaceutical Research</i> , 2005, 22, 148-152.	1.7	189
10	A simple relationship between dielectric constant of mixed solvents with solvent composition and temperature. <i>International Journal of Pharmaceutics</i> , 2004, 269, 353-360.	2.6	186
11	Mucociliary clearance in patients with cystic fibrosis and in normal subjects.. <i>American Journal of Respiratory and Critical Care Medicine</i> , 1994, 150, 66-71.	2.5	181
12	Pulmonary delivery of therapeutic siRNA. <i>Advanced Drug Delivery Reviews</i> , 2012, 64, 1-15.	6.6	177
13	Formation, characterization, and fate of inhaled drug nanoparticles. <i>Advanced Drug Delivery Reviews</i> , 2011, 63, 441-455.	6.6	175
14	Functional nanoparticles exploit the bile acid pathway to overcome multiple barriers of the intestinal epithelium for oral insulin delivery. <i>Biomaterials</i> , 2018, 151, 13-23.	5.7	175
15	Effect of Design on the Performance of a Dry Powder Inhaler Using Computational Fluid Dynamics. Part 1: Grid Structure and Mouthpiece Length. <i>Journal of Pharmaceutical Sciences</i> , 2004, 93, 2863-2876.	1.6	169
16	Mathematical representation of solute solubility in supercritical carbon dioxide using empirical expressions. <i>Journal of Supercritical Fluids</i> , 2002, 24, 19-35.	1.6	166
17	The effect of inhaled mannitol on bronchial mucus clearance in cystic fibrosis patients: a pilot study. <i>European Respiratory Journal</i> , 1999, 14, 678.	3.1	164
18	Emerging inhalation aerosol devices and strategies: Where are we headed?. <i>Advanced Drug Delivery Reviews</i> , 2014, 75, 3-17.	6.6	160

#	ARTICLE	IF	CITATIONS
19	Pulmonary drug delivery by powder aerosols. <i>Journal of Controlled Release</i> , 2014, 193, 228-240.	4.8	151
20	Effect of Amino Acids on the Dispersion of Disodium Cromoglycate Powders. <i>Journal of Pharmaceutical Sciences</i> , 2005, 94, 2289-2300.	1.6	148
21	Influence of Air Flow on the Performance of a Dry Powder Inhaler Using Computational and Experimental Analyses. <i>Pharmaceutical Research</i> , 2005, 22, 1445-1453.	1.7	148
22	Amorphous powders for inhalation drug delivery. <i>Advanced Drug Delivery Reviews</i> , 2016, 100, 102-115.	6.6	146
23	A critical view on lactose-based drug formulation and device studies for dry powder inhalation: Which are relevant and what interactions to expect?. <i>Advanced Drug Delivery Reviews</i> , 2012, 64, 257-274.	6.6	141
24	Novel alternative methods for the delivery of drugs for the treatment of asthma. <i>Advanced Drug Delivery Reviews</i> , 2003, 55, 793-805.	6.6	138
25	l-Leucine as an excipient against moisture on in vitro aerosolization performances of highly hygroscopic spray-dried powders. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2016, 102, 132-141.	2.0	135
26	Feasibility of preparing nanodrugs by high-gravity reactive precipitation. <i>International Journal of Pharmaceutics</i> , 2004, 269, 267-274.	2.6	131
27	<i>In Vitro</i> / <i>In Vivo</i> Comparisons in Pulmonary Drug Delivery. <i>Journal of Aerosol Medicine and Pulmonary Drug Delivery</i> , 2008, 21, 77-84.	0.7	129
28	Inhalation of Dry Powder Mannitol Improves Clearance of Mucus in Patients with Bronchiectasis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 1999, 159, 1843-1848.	2.5	128
29	Application of flash nanoprecipitation to fabricate poorly water-soluble drug nanoparticles. <i>Acta Pharmaceutica Sinica B</i> , 2019, 9, 4-18.	5.7	124
30	Spray dried powders and powder blends of recombinant human deoxyribonuclease (rhDNase) for aerosol delivery. <i>Pharmaceutical Research</i> , 1997, 14, 431-437.	1.7	123
31	Liposomal formulations for inhalation. <i>Therapeutic Delivery</i> , 2013, 4, 1047-1072.	1.2	120
32	Mannitol as a Challenge Test to Identify Exercise-induced Bronchoconstriction in Elite Athletes. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2003, 167, 534-537.	2.5	115
33	Phage therapy for respiratory infections. <i>Advanced Drug Delivery Reviews</i> , 2018, 133, 76-86.	6.6	115
34	Effect of design on the performance of a dry powder inhaler using computational fluid dynamics. Part 2: Air inlet size. <i>Journal of Pharmaceutical Sciences</i> , 2006, 95, 1382-1392.	1.6	114
35	Stabilization of liposomes during drying. <i>Expert Opinion on Drug Delivery</i> , 2011, 8, 375-388.	2.4	114
36	Inhaled mannitol for the treatment of mucociliary dysfunction in patients with bronchiectasis: Effect on lung function, health status and sputum. <i>Respirology</i> , 2005, 10, 46-56.	1.3	110

#	ARTICLE	IF	CITATIONS
37	Biomedical application and controlled drug release of electrospun fibrous materials. <i>Materials Science and Engineering C</i> , 2018, 90, 750-763.	3.8	107
38	Production of Inhalation Phage Powders Using Spray Freeze Drying and Spray Drying Techniques for Treatment of Respiratory Infections. <i>Pharmaceutical Research</i> , 2016, 33, 1486-1496.	1.7	106
39	Influence of particle size, air flow, and inhaler device on the dispersion of mannitol powders as aerosols. <i>Pharmaceutical Research</i> , 1999, 16, 1098-1103.	1.7	103
40	Influence of Humidity on the Electrostatic Charge and Aerosol Performance of Dry Powder Inhaler Carrier based Systems. <i>Pharmaceutical Research</i> , 2007, 24, 963-970.	1.7	103
41	Ciprofloxacin-loaded sodium alginate/poly (lactic-co-glycolic acid) electrospun fibrous mats for wound healing. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2018, 123, 42-49.	2.0	103
42	Influence of Mouthpiece Geometry on the Aerosol Delivery Performance of a Dry Powder Inhaler. <i>Pharmaceutical Research</i> , 2007, 24, 1450-1456.	1.7	101
43	What is a Suitable Dissolution Method for Drug Nanoparticles?. <i>Pharmaceutical Research</i> , 2008, 25, 1696-1701.	1.7	101
44	The Role of Capsule on the Performance of a Dry Powder Inhaler Using Computational and Experimental Analyses. <i>Pharmaceutical Research</i> , 2005, 22, 923-932.	1.7	100
45	Effect of particle size of dry powder mannitol on the lung deposition in healthy volunteers. <i>International Journal of Pharmaceutics</i> , 2008, 349, 314-322.	2.6	97
46	CFD-DEM investigation of the dispersion mechanisms in commercial dry powder inhalers. <i>Powder Technology</i> , 2013, 240, 19-24.	2.1	97
47	Limitation of Determination of Surface Fractal Dimension Using N ₂ Adsorption Isotherms and Modified Frenkel-Halsey-Hill Theory. <i>Langmuir</i> , 2003, 19, 2632-2638.	1.6	96
48	Inhalation of dry-powder mannitol increases mucociliary clearance. <i>European Respiratory Journal</i> , 1997, 10, 2449-2454.	3.1	94
49	Dry Powder Aerosol Delivery Systems: Current and Future Research Directions. <i>Journal of Aerosol Medicine and Pulmonary Drug Delivery</i> , 2006, 19, 21-27.	1.2	94
50	Isoniazid Proliposome Powders for Inhalation—Preparation, Characterization and Cell Culture Studies. <i>International Journal of Molecular Sciences</i> , 2011, 12, 4414-4434.	1.8	92
51	In vitro and in vivo aspects of cascade impactor tests and inhaler performance: A review. <i>AAPS PharmSciTech</i> , 2007, 8, 237-248.	1.5	91
52	Pulmonary Formulations: What Remains to be Done?. <i>Journal of Aerosol Medicine and Pulmonary Drug Delivery</i> , 2010, 23, S-5-S-23.	0.7	91
53	The 24-h Effect of Mannitol on the Clearance of Mucus in Patients With Bronchiectasis. <i>Chest</i> , 2001, 119, 414-421.	0.4	90
54	Preparation and characterisation of controlled release co-spray dried drug-polymer microparticles for inhalation 2: Evaluation of in vitro release profiling methodologies for controlled release respiratory aerosols. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2008, 70, 145-152.	2.0	90

#	ARTICLE	IF	CITATIONS
55	Co-spray-dried mannitolâ€“ciprofloxacin dry powder inhaler formulation for cystic fibrosis and chronic obstructive pulmonary disease. <i>European Journal of Pharmaceutical Sciences</i> , 2010, 40, 239-247.	1.9	90
56	Physicochemical Characterization and Stability of Rifampicin Liposome Dry Powder Formulations for Inhalation. <i>Journal of Pharmaceutical Sciences</i> , 2009, 98, 628-639.	1.6	88
57	Fexofenadine Decreases Sensitivity to and Montelukast Improves Recovery from Inhaled Mannitol. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2001, 163, 1420-1425.	2.5	87
58	Physical Stability of Salmon Calcitonin Spray-Dried Powders for Inhalation. <i>Journal of Pharmaceutical Sciences</i> , 2004, 93, 792-804.	1.6	86
59	Electrostatic charge characterization of pharmaceutical aerosols using electrical low-pressure impaction (ELPI). <i>Journal of Aerosol Science</i> , 2004, 35, 755-764.	1.8	86
60	A novel dry powder inhalable formulation incorporating three first-line anti-tubercular antibiotics. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2013, 83, 285-292.	2.0	86
61	Production of highly stable spray dried phage formulations for treatment of <i>Pseudomonas aeruginosa</i> lung infection. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2017, 121, 1-13.	2.0	84
62	Generation of micro-particles of proteins for aerosol delivery using high pressure modified carbon dioxide. <i>Pharmaceutical Research</i> , 2000, 17, 1360-1366.	1.7	82
63	The Role of Particle Properties in Pharmaceutical Powder Inhalation Formulations. <i>Journal of Aerosol Medicine and Pulmonary Drug Delivery</i> , 2002, 15, 325-330.	1.2	82
64	Numerical modelling of the breakage of loose agglomerates of fine particles. <i>Powder Technology</i> , 2009, 196, 213-221.	2.1	82
65	Dry powder aerosol drug deliveryâ€”Opportunities for colloid and surface scientists. <i>Colloids and Surfaces A: Physicochemical and Engineering Aspects</i> , 2006, 284-285, 50-55.	2.3	81
66	Micro-particle corrugation, adhesion and inhalation aerosol efficiency. <i>European Journal of Pharmaceutical Sciences</i> , 2008, 35, 12-18.	1.9	80
67	Fundamentals of aerosol therapy in critical care. <i>Critical Care</i> , 2016, 20, 269.	2.5	78
68	Numerical study of the effects of particle size and polydispersity on the agglomerate dispersion in a cyclonic flow. <i>Chemical Engineering Journal</i> , 2010, 164, 432-441.	6.6	77
69	Inhaled anti-infective chemotherapy for respiratory tract infections: Successes, challenges and the road ahead. <i>Advanced Drug Delivery Reviews</i> , 2015, 85, 65-82.	6.6	75
70	Design of PLGA-based depot delivery systems for biopharmaceuticals prepared by spray drying. <i>International Journal of Pharmaceutics</i> , 2016, 498, 82-95.	2.6	75
71	Effect of particle size, air flow and inhaler device on the aerosolisation of disodium cromoglycate powders. <i>International Journal of Pharmaceutics</i> , 2000, 206, 75-83.	2.6	74
72	The Influence of Drug Morphology on Aerosolisation Efficiency of Dry Powder Inhaler Formulations. <i>Journal of Pharmaceutical Sciences</i> , 2008, 97, 2780-2788.	1.6	74

#	ARTICLE	IF	CITATIONS
73	Budesonide reduces sensitivity and reactivity to inhaled mannitol in asthmatic subjects. <i>Respirology</i> , 2002, 7, 37-44.	1.3	73
74	Effects of storage conditions on the stability of spray dried, inhalable bacteriophage powders. <i>International Journal of Pharmaceutics</i> , 2017, 521, 141-149.	2.6	73
75	Anti-Tuberculosis Bacteriophage D29 Delivery with a Vibrating Mesh Nebulizer, Jet Nebulizer, and Soft Mist Inhaler. <i>Pharmaceutical Research</i> , 2017, 34, 2084-2096.	1.7	71
76	Solubility Prediction of Paracetamol in Binary and Ternary Solvent Mixtures Using Jouyban-Acree Model. <i>Chemical and Pharmaceutical Bulletin</i> , 2006, 54, 428-431.	0.6	69
77	The use of computational approaches in inhaler development. <i>Advanced Drug Delivery Reviews</i> , 2012, 64, 312-322.	6.6	69
78	Synergistic Antibiotic Combination Powders of Colistin and Rifampicin Provide High Aerosolization Efficiency and Moisture Protection. <i>AAPS Journal</i> , 2014, 16, 37-47.	2.2	69
79	Powder Production and Particle Engineering for Dry Powder Inhaler Formulations. <i>Current Pharmaceutical Design</i> , 2015, 21, 3902-3916.	0.9	69
80	Influence of solvent evaporation rate and formulation factors on solid dispersion physical stability. <i>European Journal of Pharmaceutical Sciences</i> , 2011, 44, 610-620.	1.9	68
81	Cospray Dried Antibiotics for Dry Powder Lung Delivery. <i>Journal of Pharmaceutical Sciences</i> , 2008, 97, 3356-3366.	1.6	67
82	Enhanced dissolution of inhalable cyclosporine nano-matrix particles with mannitol as matrix former. <i>International Journal of Pharmaceutics</i> , 2011, 420, 34-42.	2.6	67
83	Markers of airway inflammation and airway hyperresponsiveness in patients with well-controlled asthma. <i>European Respiratory Journal</i> , 2001, 18, 444-450.	3.1	66
84	Production of salbutamol sulfate for inhalation by high-gravity controlled antisolvent precipitation. <i>International Journal of Pharmaceutics</i> , 2007, 331, 93-98.	2.6	66
85	Electrostatic charge characteristics of aerosols produced from metered dose inhalers. <i>Journal of Pharmaceutical Sciences</i> , 2005, 94, 2789-2799.	1.6	65
86	Solubility Prediction in Supercritical CO ₂ Using Minimum Number of Experiments. <i>Journal of Pharmaceutical Sciences</i> , 2002, 91, 1287-1295.	1.6	64
87	Sensitivity and Validity of Three Bronchial Provocation Tests To Demonstrate the Effect of Inhaled Corticosteroids in Asthma. <i>Chest</i> , 2003, 124, 1341-1349.	0.4	64
88	Bacteriophage PEV20 and Ciprofloxacin Combination Treatment Enhances Removal of <i>Pseudomonas aeruginosa</i> Biofilm Isolated from Cystic Fibrosis and Wound Patients. <i>AAPS Journal</i> , 2019, 21, 49.	2.2	64
89	Effect of Relative Humidity on the Electrostatic Charge Properties of Dry Powder Inhaler Aerosols. <i>Pharmaceutical Research</i> , 2008, 25, 277-288.	1.7	63
90	Constant size, variable density aerosol particles by ultrasonic spray freeze drying. <i>International Journal of Pharmaceutics</i> , 2012, 427, 185-191.	2.6	63

#	ARTICLE	IF	CITATIONS
91	Advances in Device and Formulation Technologies for Pulmonary Drug Delivery. <i>AAPS PharmSciTech</i> , 2014, 15, 882-897.	1.5	63
92	Proof-of-Principle Study in a Murine Lung Infection Model of Antipseudomonal Activity of Phage PEV20 in a Dry-Powder Formulation. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	1.4	63
93	Synergy of nebulized phage PEV20 and ciprofloxacin combination against <i>Pseudomonas aeruginosa</i> . <i>International Journal of Pharmaceutics</i> , 2018, 551, 158-165.	2.6	63
94	Encapsulation and release of doxycycline from electrospray-generated PLGA microspheres: Effect of polymer end groups. <i>International Journal of Pharmaceutics</i> , 2019, 564, 1-9.	2.6	63
95	Pharmaceutical strategies to extend pulmonary exposure of inhaled medicines. <i>Acta Pharmaceutica Sinica B</i> , 2021, 11, 2565-2584.	5.7	63
96	Agglomeration of fine particles subjected to centripetal compaction. <i>Powder Technology</i> , 2008, 184, 122-129.	2.1	62
97	Effect of Device Design on the Aerosolization of a Carrier-Based Dry Powder Inhaler—a Case Study on Aerolizer® Foradile®. <i>AAPS Journal</i> , 2013, 15, 511-522.	2.2	62
98	Sonocrystallisation of sodium chloride particles for inhalation. <i>Chemical Engineering Science</i> , 2007, 62, 2445-2453.	1.9	61
99	Application of the periodic bond chain (PBC) theory and attachment energy consideration to derive the crystal morphology of hexamethylmelamine. <i>Pharmaceutical Research</i> , 1993, 10, 1052-1058.	1.7	60
100	The Influence of Mechanical Processing of Dry Powder Inhaler Carriers on Drug Aerosolization Performance. <i>Journal of Pharmaceutical Sciences</i> , 2007, 96, 1331-1341.	1.6	60
101	Dry powder inhalable formulations for anti-tubercular therapy. <i>Advanced Drug Delivery Reviews</i> , 2016, 102, 83-101.	6.6	60
102	TLR2-targeted secreted proteins from <i>Mycobacterium tuberculosis</i> are protective as powdered pulmonary vaccines. <i>Vaccine</i> , 2013, 31, 4322-4329.	1.7	59
103	Critical Solvent Properties Affecting the Particle Formation Process and Characteristics of Celecoxib-Loaded PLGA Microparticles via Spray-Drying. <i>Pharmaceutical Research</i> , 2013, 30, 1065-1076.	1.7	59
104	Budesonide nanocrystal-loaded hyaluronic acid microparticles for inhalation: In vitro and in vivo evaluation. <i>Carbohydrate Polymers</i> , 2018, 181, 1143-1152.	5.1	59
105	Evaluation of biomimetically synthesized mesoporous silica nanoparticles as drug carriers: Structure, wettability, degradation, biocompatibility and brain distribution. <i>Materials Science and Engineering C</i> , 2019, 94, 453-464.	3.8	59
106	Aerodynamic properties of elongated particles of cromoglycic acid. <i>Journal of Aerosol Science</i> , 1989, 20, 157-168.	1.8	58
107	What is the role of particle morphology in pharmaceutical powder aerosols?. <i>Expert Opinion on Drug Delivery</i> , 2008, 5, 909-914.	2.4	58
108	Alginate modified-PLGA nanoparticles entrapping amikacin and moxifloxacin as a novel host-directed therapy for multidrug-resistant tuberculosis. <i>Journal of Drug Delivery Science and Technology</i> , 2019, 52, 642-651.	1.4	58

#	ARTICLE	IF	CITATIONS
109	Design and Solidification of Fast-Releasing Clofazimine Nanoparticles for Treatment of Cryptosporidiosis. <i>Molecular Pharmaceutics</i> , 2017, 14, 3480-3488.	2.3	57
110	Effect of storage temperature on the stability of spray dried bacteriophage powders. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2018, 127, 213-222.	2.0	57
111	In Vitro Aerosol Performance and Dose Uniformity between the Foradile® Aerolizer® and the Oxis® Turbuhaler®. <i>Journal of Aerosol Medicine and Pulmonary Drug Delivery</i> , 2001, 14, 495-501.	1.2	56
112	Coughing During Mannitol Challenge Is Associated With Asthma. <i>Chest</i> , 2004, 125, 1985-1992.	0.4	56
113	Quality by design thinking in the development of long-acting injectable PLGA/PLA-based microspheres for peptide and protein drug delivery. <i>International Journal of Pharmaceutics</i> , 2020, 585, 119441.	2.6	56
114	Aerosol Delivery of Nanoparticles in Uniform Mannitol Carriers Formulated by Ultrasonic Spray Freeze Drying. <i>Pharmaceutical Research</i> , 2013, 30, 2891-2901.	1.7	55
115	Ultrafast star-shaped acoustic micromixer for high throughput nanoparticle synthesis. <i>Lab on A Chip</i> , 2020, 20, 582-591.	3.1	55
116	Dry powder pharmaceutical biologics for inhalation therapy. <i>Advanced Drug Delivery Reviews</i> , 2021, 172, 64-79.	6.6	53
117	Novel antimicrobial agents for combating antibiotic-resistant bacteria. <i>Advanced Drug Delivery Reviews</i> , 2022, 187, 114378.	6.6	53
118	A Unified Cosolvency Model for Calculating Solute Solubility in Mixed Solvents. <i>Chemical and Pharmaceutical Bulletin</i> , 2005, 53, 634-637.	0.6	52
119	Human oligopeptide transporter 2 (PEPT2) mediates cellular uptake of polymyxins. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 403-412.	1.3	52
120	Controlled release antibiotics for dry powder lung delivery. <i>Drug Development and Industrial Pharmacy</i> , 2010, 36, 119-126.	0.9	51
121	Particle size dependence of polymorphism in spray-dried mannitol. <i>European Journal of Pharmaceutical Sciences</i> , 2011, 44, 41-48.	1.9	51
122	SPECT Imaging for Radioaerosol Deposition and Clearance Studies. <i>Journal of Aerosol Medicine and Pulmonary Drug Delivery</i> , 2006, 19, 8-20.	1.2	50
123	Particle Aerosolisation and Break-up in Dry Powder Inhalers 1: Evaluation and Modelling of Venturi Effects for Agglomerated Systems. <i>Pharmaceutical Research</i> , 2010, 27, 1367-1376.	1.7	50
124	Electrostatics in pharmaceutical solids. <i>Chemical Engineering Science</i> , 2015, 125, 225-237.	1.9	50
125	Advances in combination therapy of lung cancer: Rationales, delivery technologies and dosage regimens. <i>Journal of Controlled Release</i> , 2017, 260, 78-91.	4.8	50
126	Inhaled powder formulation of naked siRNA using spray drying technology with l-leucine as dispersion enhancer. <i>International Journal of Pharmaceutics</i> , 2017, 530, 40-52.	2.6	50

#	ARTICLE	IF	CITATIONS
127	Topical application of bacteriophages for treatment of wound infections. <i>Translational Research</i> , 2020, 220, 153-166.	2.2	50
128	Drug delivery: A key factor in realising the full therapeutic potential of drugs. <i>Drug Development Research</i> , 1999, 46, 316-327.	1.4	49
129	Responsiveness to Three Bronchial Provocation Tests in Patients With Asthma. <i>Chest</i> , 2003, 124, 2171-2177.	0.4	49
130	Prediction of aerodynamic diameter of particles with rough surfaces. <i>Powder Technology</i> , 2004, 147, 64-78.	2.1	49
131	A novel production method for inhalable cyclosporine A powders by confined liquid impinging jet precipitation. <i>Journal of Aerosol Science</i> , 2008, 39, 500-509.	1.8	49
132	Lactose Composite Carriers for Respiratory Delivery. <i>Pharmaceutical Research</i> , 2009, 26, 802-810.	1.7	49
133	Colistin Powders with High Aerosolisation Efficiency for Respiratory Infection: Preparation and In Vitro Evaluation. <i>Journal of Pharmaceutical Sciences</i> , 2013, 102, 3736-3747.	1.6	49
134	Development and Characterization of an In Vitro Release Assay for Liposomal Ciprofloxacin for Inhalation. <i>Journal of Pharmaceutical Sciences</i> , 2014, 103, 314-327.	1.6	49
135	Formulation of pH responsive peptides as inhalable dry powders for pulmonary delivery of nucleic acids. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2014, 86, 64-73.	2.0	49
136	Modifying the Release Properties of Liposomes Toward Personalized Medicine. <i>Journal of Pharmaceutical Sciences</i> , 2014, 103, 1851-1862.	1.6	49
137	Treatment of acute lung inflammation by pulmonary delivery of anti-TNF- α siRNA with PAMAM dendrimers in a murine model. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2020, 156, 114-120.	2.0	49
138	Inhalable combination powder formulations of phage and ciprofloxacin for <i>P. aeruginosa</i> respiratory infections. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2019, 142, 543-552.	2.0	48
139	A solid-state NMR study of protein hydration and stability. <i>Pharmaceutical Research</i> , 1998, 15, 1816-1821.	1.7	47
140	A Cosolvency Model to Predict Solubility of Drugs at Several Temperatures from a Limited Number of Solubility Measurements.. <i>Chemical and Pharmaceutical Bulletin</i> , 2002, 50, 594-599.	0.6	47
141	Measuring charge and mass distributions in dry powder inhalers using the electrical Next Generation Impactor (eNCl). <i>European Journal of Pharmaceutical Sciences</i> , 2009, 38, 88-94.	1.9	47
142	Ciprofloxacin nanocrystals liposomal powders for controlled drug release via inhalation. <i>International Journal of Pharmaceutics</i> , 2019, 566, 641-651.	2.6	47
143	Regional deposition of inhaled hygroscopic aerosols: in vivo SPECT compared with mathematical modeling. <i>Journal of Applied Physiology</i> , 1996, 81, 374-383.	1.2	46
144	Modeling acid dissociation constant of analytes in binary solvents at various temperatures using Jouyban's Acree model. <i>Thermochimica Acta</i> , 2005, 428, 119-123.	1.2	46

#	ARTICLE	IF	CITATIONS
145	Formulation of Biologically-Inspired Silk-Based Drug Carriers for Pulmonary Delivery Targeted for Lung Cancer. <i>Scientific Reports</i> , 2015, 5, 11878.	1.6	46
146	Investigation of L-leucine in reducing the moisture-induced deterioration of spray-dried salbutamol sulfate powder for inhalation. <i>International Journal of Pharmaceutics</i> , 2017, 530, 30-39.	2.6	46
147	Inhaler Technique in Asthma: How Does It Relate to Patients' Preferences and Attitudes Toward Their Inhalers?. <i>Journal of Aerosol Medicine and Pulmonary Drug Delivery</i> , 2017, 30, 42-52.	0.7	46
148	Storage stability of inhalable phage powders containing lactose at ambient conditions. <i>International Journal of Pharmaceutics</i> , 2019, 560, 11-18.	2.6	46
149	Aggregation of rhDNase occurred during the compression of KBr pellets used for FTIR spectroscopy. <i>Pharmaceutical Research</i> , 1996, 13, 238-242.	1.7	45
150	Nedocromil Sodium Inhibits Responsiveness to Inhaled Mannitol in Asthmatic Subjects. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2000, 161, 2096-2099.	2.5	45
151	Pharmacokinetics/Pharmacodynamics of Pulmonary Delivery of Colistin against <i>Pseudomonas aeruginosa</i> in a Mouse Lung Infection Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	1.4	45
152	Inhaled antibiotics to treat lung infection. <i>Pharmaceutical Patent Analyst</i> , 2013, 2, 647-663.	0.4	44
153	A Rifapentine-Containing Inhaled Triple Antibiotic Formulation for Rapid Treatment of Tubercular Infection. <i>Pharmaceutical Research</i> , 2014, 31, 1239-1253.	1.7	44
154	Effect of powder polydispersity on aerosol generation. <i>Journal of Pharmacy and Pharmaceutical Sciences</i> , 2002, 5, 162-8.	0.9	44
155	Influence of compaction on the intrinsic dissolution rate of modified acetaminophen and adipic acid crystals. <i>International Journal of Pharmaceutics</i> , 1989, 57, 117-124.	2.6	43
156	A Novel Inhalable Form of Rifapentine. <i>Journal of Pharmaceutical Sciences</i> , 2014, 103, 1411-1421.	1.6	43
157	Effects of Surface Composition on the Aerosolisation and Dissolution of Inhaled Antibiotic Combination Powders Consisting of Colistin and Rifampicin. <i>AAPS Journal</i> , 2016, 18, 372-384.	2.2	43
158	Protection of hydrophobic amino acids against moisture-induced deterioration in the aerosolization performance of highly hygroscopic spray-dried powders. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2017, 119, 224-234.	2.0	43
159	Overcoming Dose Limitations Using the Orbital [®] Multi-Breath Dry Powder Inhaler. <i>Journal of Aerosol Medicine and Pulmonary Drug Delivery</i> , 2014, 27, 138-147.	0.7	42
160	Rifapentine-loaded PLGA microparticles for tuberculosis inhaled therapy: Preparation and in vitro aerosol characterization. <i>European Journal of Pharmaceutical Sciences</i> , 2016, 88, 1-11.	1.9	42
161	How Much Surface Coating of Hydrophobic Azithromycin Is Sufficient to Prevent Moisture-Induced Decrease in Aerosolisation of Hygroscopic Amorphous Colistin Powder?. <i>AAPS Journal</i> , 2016, 18, 1213-1224.	2.2	42
162	Porous and highly dispersible voriconazole dry powders produced by spray freeze drying for pulmonary delivery with efficient lung deposition. <i>International Journal of Pharmaceutics</i> , 2019, 560, 144-154.	2.6	42

#	ARTICLE	IF	CITATIONS
163	Solubility Prediction of Anthracene in Mixed Solvents Using a Minimum Number of Experimental Data.. Chemical and Pharmaceutical Bulletin, 2002, 50, 21-25.	0.6	41
164	Evaluation on the Use of Confined Liquid Impinging Jets for the Synthesis of Nanodrug Particles. Drug Development and Industrial Pharmacy, 2008, 34, 59-64.	0.9	41
165	Design and evaluation of poly(dl-lactic-co-glycolic acid) nanocomposite particles containing salmon calcitonin for inhalation. European Journal of Pharmaceutical Sciences, 2012, 46, 374-380.	1.9	41
166	One-Step Production of Protein-Loaded PLGA Microparticles via Spray Drying Using 3-Fluid Nozzle. Pharmaceutical Research, 2014, 31, 1967-1977.	1.7	41
167	Inhalable Dry Powder Formulations of siRNA and pH-Responsive Peptides with Antiviral Activity Against H1N1 Influenza Virus. Molecular Pharmaceutics, 2015, 12, 910-921.	2.3	41
168	Aerosolized Polymyxin B for Treatment of Respiratory Tract Infections: Determination of Pharmacokinetic-Pharmacodynamic Indices for Aerosolized Polymyxin B against Pseudomonas aeruginosa in a Mouse Lung Infection Model. Antimicrobial Agents and Chemotherapy, 2017, 61, .	1.4	41
169	Inhalable co-amorphous budesonide-arginine dry powders prepared by spray drying. International Journal of Pharmaceutics, 2019, 565, 1-8.	2.6	41
170	A Solid-State NMR Study of Protein Mobility in Lyophilized Proteinâ€“Sugar Powders. Journal of Pharmaceutical Sciences, 2002, 91, 943-951.	1.6	40
171	The Use of Organic Vapor Sorption to Determine Low Levels of Amorphous Content in Processed Pharmaceutical Powders. Drug Development and Industrial Pharmacy, 2007, 33, 91-97.	0.9	40
172	Focused-ion-beam Milling: A Novel Approach to Probing the Interior of Particles Used for Inhalation Aerosols. Pharmaceutical Research, 2007, 24, 1608-1617.	1.7	40
173	Inhalable siRNA-loaded nano-embedded microparticles engineered using microfluidics and spray drying. European Journal of Pharmaceutics and Biopharmaceutics, 2017, 120, 9-21.	2.0	40
174	Inhalable clarithromycin liposomal dry powders using ultrasonic spray freeze drying. Powder Technology, 2017, 305, 63-70.	2.1	40
175	Solubility Prediction for Furosemide in Water-Cosolvent Mixtures Using the Minimum Number of Experiments. Drug Development and Industrial Pharmacy, 2001, 27, 577-583.	0.9	39
176	Composite carriers improve the aerosolisation efficiency of drugs for respiratory delivery. Journal of Aerosol Science, 2008, 39, 82-93.	1.8	39
177	Solid State Characterization of Spray-Dried Powders of Recombinant Human Deoxyribonuclease (RhDNase)â€“. Journal of Pharmaceutical Sciences, 1998, 87, 647-654.	1.6	38
178	Aerosol deposition and clearance measurement: a novel technique using dynamic SPET. European Journal of Nuclear Medicine and Molecular Imaging, 2001, 28, 1365-1372.	2.2	38
179	Designing CAF-adjuvanted dry powder vaccines: Spray drying preserves the adjuvant activity of CAF01. Journal of Controlled Release, 2013, 167, 256-264.	4.8	38
180	Delivery of inhalation drugs to children for asthma and other respiratory diseases. Advanced Drug Delivery Reviews, 2014, 73, 83-88.	6.6	38

#	ARTICLE	IF	CITATIONS
181	Multi-Scale Modelling of Powder Dispersion in a Carrier-Based Inhalation System. <i>Pharmaceutical Research</i> , 2015, 32, 2086-2096.	1.7	38
182	Formation of drug nanocrystals under nanoconfinement afforded by liposomes. <i>RSC Advances</i> , 2016, 6, 6223-6233.	1.7	38
183	Electrospinnability of Poly Lactic-co-glycolic Acid (PLGA): the Role of Solvent Type and Solvent Composition. <i>Pharmaceutical Research</i> , 2017, 34, 738-749.	1.7	38
184	Nebulization effects on structural stability of bacteriophage PEV 44. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2018, 125, 124-130.	2.0	38
185	Using two-fluid nozzle for spray freeze drying to produce porous powder formulation of naked siRNA for inhalation. <i>International Journal of Pharmaceutics</i> , 2018, 552, 67-75.	2.6	38
186	Application of Spray-drying and Electro spraying/Electrospinning for Poorly Watersoluble Drugs: A Particle Engineering Approach. <i>Current Pharmaceutical Design</i> , 2014, 20, 325-348.	0.9	38
187	Influence of Flow Rate on Aerosol Particle Size Distributions from Pressurized and Breath-Actuated Inhalers. <i>Journal of Aerosol Medicine and Pulmonary Drug Delivery</i> , 1998, 11, 231-245.	1.2	37
188	Changes in Lung Deposition of Aerosols due to Hygroscopic Growth: A Fast SPECT Study. <i>Journal of Aerosol Medicine and Pulmonary Drug Delivery</i> , 2002, 15, 307-311.	1.2	37
189	Characterization of pharmaceutical powder inhalers: estimation of energy input for powder dispersion and effect of capsule device configuration. <i>Journal of Aerosol Science</i> , 2002, 33, 999-1008.	1.8	37
190	The Influence of Flow Rate on the Aerosol Deposition Profile and Electrostatic Charge of Single and Combination Metered Dose Inhalers. <i>Pharmaceutical Research</i> , 2009, 26, 2639-2646.	1.7	36
191	CFD-DEM investigation of the effect of agglomerate-agglomerate collision on dry powder aerosolisation. <i>Journal of Aerosol Science</i> , 2016, 92, 109-121.	1.8	36
192	Inhaled hyaluronic acid microparticles extended pulmonary retention and suppressed systemic exposure of a short-acting bronchodilator. <i>Carbohydrate Polymers</i> , 2017, 172, 197-204.	5.1	36
193	Cocrystal Engineering of Itraconazole with Suberic Acid via Rotary Evaporation and Spray Drying. <i>Crystal Growth and Design</i> , 2019, 19, 2736-2745.	1.4	36
194	Inhalation delivery technology for genome-editing of respiratory diseases. <i>Advanced Drug Delivery Reviews</i> , 2021, 168, 217-228.	6.6	36
195	Bacteriophage-Delivering Hydrogels: Current Progress in Combating Antibiotic Resistant Bacterial Infection. <i>Antibiotics</i> , 2021, 10, 130.	1.5	36
196	Particle engineering principles and technologies for pharmaceutical biologics. <i>Advanced Drug Delivery Reviews</i> , 2021, 174, 140-167.	6.6	36
197	Nanotechnology Versus other Techniques in Improving Drug Dissolution. <i>Current Pharmaceutical Design</i> , 2014, 20, 474-482.	0.9	36
198	Inhalation drug delivery devices and emerging technologies. <i>Expert Opinion on Therapeutic Patents</i> , 2003, 13, 1333-1343.	2.4	35

#	ARTICLE	IF	CITATIONS
199	Preparation and characterisation of controlled release co-spray dried drug-polymer microparticles for inhalation 1: Influence of polymer concentration on physical and in vitro characteristics. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2008, 69, 486-495.	2.0	35
200	Formation of Protein Nano-Matrix Particles with Controlled Surface Architecture for Respiratory Drug Delivery. <i>Pharmaceutical Research</i> , 2011, 28, 788-796.	1.7	35
201	Microfluidic-assisted bacteriophage encapsulation into liposomes. <i>International Journal of Pharmaceutics</i> , 2018, 545, 176-182.	2.6	35
202	Inhalable bacteriophage powders: Glass transition temperature and bioactivity stabilization. <i>Bioengineering and Translational Medicine</i> , 2020, 5, e10159.	3.9	35
203	Preparation of Inhalable Salbutamol Sulphate Using Reactive High Gravity Controlled Precipitation. <i>Journal of Pharmaceutical Sciences</i> , 2008, 97, 944-949.	1.6	34
204	Preparation and Evaluation of Controlled Release Microparticles for Respiratory Protein Therapy. <i>Journal of Pharmaceutical Sciences</i> , 2009, 98, 2709-2717.	1.6	34
205	Synergistic activity of phage PEV20-ciprofloxacin combination powder formulation-A proof-of-principle study in a <i>P. aeruginosa</i> lung infection model. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2021, 158, 166-171.	2.0	34
206	Design and evaluation of inhalable chitosan-modified poly (dl-lactic-co-glycolic acid) nanocomposite particles. <i>European Journal of Pharmaceutical Sciences</i> , 2012, 47, 235-243.	1.9	33
207	Electrostatics in pharmaceutical aerosols for inhalation. <i>Therapeutic Delivery</i> , 2013, 4, 981-1002.	1.2	33
208	Effects of ramp-up of inspired airflow on in vitro aerosol dose delivery performance for certain dry powder inhalers. <i>European Journal of Pharmaceutical Sciences</i> , 2016, 84, 46-54.	1.9	33
209	Recent advances in electrospun for drug delivery purpose. <i>Journal of Drug Targeting</i> , 2019, 27, 270-282.	2.1	33
210	CFD modelling of air and particle flows in different airway models. <i>Journal of Aerosol Science</i> , 2019, 134, 14-28.	1.8	33
211	Amino acids as stabilizers for spray-dried simvastatin powder for inhalation. <i>International Journal of Pharmaceutics</i> , 2019, 572, 118724.	2.6	33
212	Pharmacokinetics/pharmacodynamics of antipseudomonal bacteriophage therapy in rats: a proof-of-concept study. <i>Clinical Microbiology and Infection</i> , 2020, 26, 1229-1235.	2.8	33
213	Introduction of the Electrical Next Generation Impactor (eNGI) and Investigation of its Capabilities for the Study of Pressurized Metered Dose Inhalers. <i>Pharmaceutical Research</i> , 2009, 26, 431-437.	1.7	32
214	Can low-dose combination products for inhalation be formulated in single crystalline particles?. <i>European Journal of Pharmaceutical Sciences</i> , 2010, 40, 16-24.	1.9	32
215	Agglomerate strength and dispersion of pharmaceutical powders. <i>Journal of Aerosol Science</i> , 2011, 42, 285-294.	1.8	32
216	Validation of Radiolabeling of Drug Formulations for Aerosol Deposition Assessment of Orally Inhaled Products. <i>Journal of Aerosol Medicine and Pulmonary Drug Delivery</i> , 2012, 25, S-6-S-9.	0.7	32

#	ARTICLE	IF	CITATIONS
217	Standardization of Techniques for Using Single-Photon Emission Computed Tomography (SPECT) for Aerosol Deposition Assessment of Orally Inhaled Products. <i>Journal of Aerosol Medicine and Pulmonary Drug Delivery</i> , 2012, 25, S-29-S-51.	0.7	32
218	Lipophilic prodrugs of apomorphine I: Preparation, characterisation, and in vitro enzymatic hydrolysis in biorelevant media. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2015, 89, 216-223.	2.0	32
219	Respirable Form of Crystals of Cromoglycic Acid. <i>Journal of Pharmaceutical Sciences</i> , 1989, 78, 176-180.	1.6	31
220	Inhaled mannitol identifies methacholine-responsive children with active asthma. , 2000, 29, 291-298.		31
221	Prediction of treatment-response to inhaled corticosteroids by mannitol-challenge test in COPD. A proof of concept. <i>Pulmonary Pharmacology and Therapeutics</i> , 2005, 18, 83-88.	1.1	31
222	Effects of mechanical impaction on aerosol performance of particles with different surface roughness. <i>Powder Technology</i> , 2013, 236, 164-170.	2.1	31
223	Synergistic combination dry powders for inhaled antimicrobial therapy: Formulation, characterization and in vitro evaluation. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2013, 83, 275-284.	2.0	31
224	Engineering of budesonide-loaded lipid-polymer hybrid nanoparticles using a quality-by-design approach. <i>International Journal of Pharmaceutics</i> , 2018, 548, 740-746.	2.6	31
225	Jet nebulization of bacteriophages with different tail morphologies – Structural effects. <i>International Journal of Pharmaceutics</i> , 2019, 554, 322-326.	2.6	31
226	Modeling of a spray drying method to produce ciprofloxacin nanocrystals inside the liposomes utilizing a response surface methodology: Box-Behnken experimental design. <i>International Journal of Pharmaceutics</i> , 2021, 597, 120277.	2.6	31
227	Personalizing aerosol medicine: development of delivery systems tailored to the individual. <i>Therapeutic Delivery</i> , 2010, 1, 667-682.	1.2	30
228	Electrostatics of pharmaceutical inhalation aerosols. <i>Journal of Pharmacy and Pharmacology</i> , 2010, 61, 1587-1599.	1.2	30
229	Numerical investigation of the de-agglomeration mechanisms of fine powders on mechanical impaction. <i>Journal of Aerosol Science</i> , 2011, 42, 811-819.	1.8	30
230	<i>In Vitro</i> Assessment of Dose Delivery Performance of Dry Powders for Inhalation. <i>Aerosol Science and Technology</i> , 2014, 48, 1099-1110.	1.5	30
231	De-agglomeration Effect of the US Pharmacopeia and Alberta Throats on Carrier-Based Powders in Commercial Inhalation Products. <i>AAPS Journal</i> , 2015, 17, 1407-1416.	2.2	30
232	The Effects of Relative Humidity on the Flowability and Dispersion Performance of Lactose Mixtures. <i>Materials</i> , 2017, 10, 592.	1.3	30
233	Numerical Comparison of Nasal Aerosol Administration Systems for Efficient Nose-to-Brain Drug Delivery. <i>Pharmaceutical Research</i> , 2018, 35, 5.	1.7	30
234	Pharmaceutical microparticle engineering with electrospraying: the role of mixed solvent systems in particle formation and characteristics. <i>Journal of Materials Science: Materials in Medicine</i> , 2015, 26, 61.	1.7	29

#	ARTICLE	IF	CITATIONS
235	Effect of thermal and shear stresses in the spray drying process on the stability of siRNA dry powders. <i>International Journal of Pharmaceutics</i> , 2019, 566, 32-39.	2.6	29
236	Regional deposition of nebulized hypodense nonisotonic solutions in the human respiratory tract. <i>European Respiratory Journal</i> , 1994, 7, 1483-1489.	3.1	28
237	Physicochemical Characterization of a New Respirable Form of Nedocromil. <i>Journal of Pharmaceutical Sciences</i> , 1995, 84, 692-696.	1.6	28
238	Deposition of aqueous aerosol of technetium-99m diethylene triamine penta-acetic acid generated and delivered by a novel system (AER x) in healthy subjects. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 1999, 26, 320-327.	3.3	28
239	Inhalation Challenge With Bovine Dander Allergens. <i>Chest</i> , 2003, 124, 383-391.	0.4	28
240	Characterisation and aerosolisation of mannitol particles produced via confined liquid impinging jets. <i>International Journal of Pharmaceutics</i> , 2009, 367, 51-57.	2.6	28
241	Pharmacokinetics and Time-Kill Study of Inhaled Antipseudomonal Bacteriophage Therapy in Mice. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 65, .	1.4	28
242	Converting nanosuspension into inhalable and redispersible nanoparticles by combined in-situ thermal gelation and spray drying. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2020, 149, 238-247.	2.0	28
243	PLGA particulate subunit tuberculosis vaccines promote humoral and Th17 responses but do not enhance control of <i>Mycobacterium tuberculosis</i> infection. <i>PLoS ONE</i> , 2018, 13, e0194620.	1.1	28
244	Effect of spacers on the electrostatic charge properties of metered dose inhaler aerosols. <i>Journal of Aerosol Science</i> , 2006, 37, 1671-1682.	1.8	27
245	Lung Deposition of Mannitol Powder Aerosol in Healthy Subjects. <i>Journal of Aerosol Medicine and Pulmonary Drug Delivery</i> , 2006, 19, 522-532.	1.2	27
246	Pure drug nanoparticles in tablets: what are the dissolution limitations?. <i>Journal of Nanoparticle Research</i> , 2010, 12, 1743-1754.	0.8	27
247	Pulmonary Delivery of the Kv1.3-Blocking Peptide HsTX1 [R14A] for the Treatment of Autoimmune Diseases. <i>Journal of Pharmaceutical Sciences</i> , 2016, 105, 650-656.	1.6	27
248	Carboxymethyl fenugreek galactomannan-g-poly(N-isopropylacrylamide-co-N,N-dimethyl-methylene-bis-acrylamide)-clay based pH/temperature-responsive nanocomposites as drug-carriers. <i>Materials Science and Engineering C</i> , 2020, 110, 110628.	3.8	27
249	Quantitative comparison of three widely-used pulmonary administration methods in vivo with radiolabeled inhalable nanoparticles. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2020, 152, 108-115.	2.0	27
250	Phage cocktail powder for <i>Pseudomonas aeruginosa</i> respiratory infections. <i>International Journal of Pharmaceutics</i> , 2021, 596, 120200.	2.6	27
251	Advances in the development of antimicrobial peptides and proteins for inhaled therapy. <i>Advanced Drug Delivery Reviews</i> , 2022, 180, 114066.	6.6	27
252	Method to Introduce Mannitol Powder to Intubated Patients to Improve Sputum Clearance. <i>Journal of Aerosol Medicine and Pulmonary Drug Delivery</i> , 2011, 24, 1-9.	0.7	26

#	ARTICLE	IF	CITATIONS
253	The effect of ethanol on the formation and physico-chemical properties of particles generated from budesonide solution-based pressurized metered-dose inhalers. <i>Drug Development and Industrial Pharmacy</i> , 2013, 39, 1625-1637.	0.9	26
254	Effect of Crystallinity on Electrostatic Charging in Dry Powder Inhaler Formulations. <i>Pharmaceutical Research</i> , 2014, 31, 1656-1664.	1.7	26
255	Porous mannitol carrier for pulmonary delivery of cyclosporine A nanoparticles. <i>AAPS Journal</i> , 2017, 19, 578-586.	2.2	26
256	Mathematical representation of apparent dissociation constants in aqueous-organic solvent mixtures. <i>International Journal of Pharmaceutics</i> , 2002, 246, 135-142.	2.6	25
257	Modeling the Entrainer Effects on Solubility of Solutes in Supercritical Carbon Dioxide. <i>Chemical and Pharmaceutical Bulletin</i> , 2005, 53, 290-295.	0.6	25
258	Simple and cost-effective powder disperser for aerosol particle size measurement. <i>Powder Technology</i> , 2008, 187, 27-36.	2.1	25
259	Scanning White-Light Interferometry as a Novel Technique to Quantify the Surface Roughness of Micron-Sized Particles for Inhalation. <i>Langmuir</i> , 2008, 24, 11307-11312.	1.6	25
260	Particle Aerosolisation and Breakup in Dry Powder Inhalers: Evaluation and Modelling of the Influence of Grid Structures for Agglomerated Systems. <i>Journal of Pharmaceutical Sciences</i> , 2011, 100, 4710-4721.	1.6	25
261	Formulation technologies to overcome unfavorable properties of peptides and proteins for pulmonary delivery. <i>Drug Discovery Today: Technologies</i> , 2012, 9, e141-e146.	4.0	25
262	Impact of molecular rearrangement of amphiphilic stabilizers on physical stability of itraconazole nanoparticles prepared by flash nanoprecipitation. <i>International Journal of Pharmaceutics</i> , 2018, 542, 221-231.	2.6	25
263	Acoustically enhanced microfluidic mixer to synthesize highly uniform nanodrugs without the addition of stabilizers. <i>International Journal of Nanomedicine</i> , 2018, Volume 13, 1353-1359.	3.3	25
264	In vitro-in vivo correlations (IVIVCs) of deposition for drugs given by oral inhalation. <i>Advanced Drug Delivery Reviews</i> , 2020, 167, 135-147.	6.6	25
265	Discrete Modelling of Powder Dispersion in Dry Powder Inhalers - A Brief Review. <i>Current Pharmaceutical Design</i> , 2015, 21, 3966-3973.	0.9	25
266	Crystal and molecular structure of methotrexate. <i>Journal of the American Chemical Society</i> , 1986, 108, 2103-2105.	6.6	24
267	Generation of Fine Powders of Recombinant Human Deoxyribonuclease Using the Aerosol Solvent Extraction System. <i>Pharmaceutical Research</i> , 2003, 20, 2028-2035.	1.7	24
268	A novel method for the production of crystalline micronised particles. <i>International Journal of Pharmaceutics</i> , 2010, 388, 114-122.	2.6	24
269	Electrostatic Charge Characteristics of Jet Nebulized Aerosols. <i>Journal of Aerosol Medicine and Pulmonary Drug Delivery</i> , 2010, 23, 149-159.	0.7	24
270	Repurposing excipients as active inhalation agents: The mannitol story. <i>Advanced Drug Delivery Reviews</i> , 2018, 133, 45-56.	6.6	24

#	ARTICLE	IF	CITATIONS
271	Phage-antibiotic Therapy as a Promising Strategy to Combat Multidrug-Resistant Infections and to Enhance Antimicrobial Efficiency. <i>Antibiotics</i> , 2022, 11, 570.	1.5	24
272	Use of Single Photon Emission Computed Tomography in Aerosol Studies. <i>Journal of Aerosol Medicine and Pulmonary Drug Delivery</i> , 1993, 6, 23-36.	1.2	23
273	A model to represent solvent effects on the chemical stability of solutes in mixed solvent systems. <i>International Journal of Pharmaceutics</i> , 2002, 243, 167-172.	2.6	23
274	Dissociation in the effect of nedocromil on mannitol-induced cough or bronchoconstriction in asthmatic subjects*. <i>Respirology</i> , 2005, 10, 442-448.	1.3	23
275	Does electrostatic charge affect powder aerosolisation?. <i>Journal of Pharmaceutical Sciences</i> , 2010, 99, 2455-2461.	1.6	23
276	Pharmacopeial methodologies for determining aerodynamic mass distributions of ultra-high dose inhaler medicines. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2010, 51, 853-857.	1.4	23
277	Aerosol Performance and Stability of Liposomes Containing Ciprofloxacin Nanocrystals. <i>Journal of Aerosol Medicine and Pulmonary Drug Delivery</i> , 2015, 28, 411-422.	0.7	23
278	Novel Inhaled Combination Powder Containing Amorphous Colistin and Crystalline Rifapentine with Enhanced Antimicrobial Activities against Planktonic Cells and Biofilm of <i>Pseudomonas aeruginosa</i> for Respiratory Infections. <i>Molecular Pharmaceutics</i> , 2015, 12, 2594-2603.	2.3	23
279	Effect of moisture on the electrostatic charge properties of metered dose inhaler aerosols. <i>Journal of Aerosol Science</i> , 2008, 39, 211-226.	1.8	22
280	Recent Advances in Controlled Release Pulmonary Therapy. <i>Current Drug Delivery</i> , 2009, 6, 404-414.	0.8	22
281	Does the United States Pharmacopeia Throat Introduce De-agglomeration of Carrier-Free Powder from Inhalers?. <i>Pharmaceutical Research</i> , 2012, 29, 1797-1807.	1.7	22
282	Novel alternatives to reduce powder retention in the dry powder inhaler during aerosolization. <i>International Journal of Pharmaceutics</i> , 2013, 452, 194-200.	2.6	22
283	Partitioning of dispersed nanoparticles in a realistic nasal passage for targeted drug delivery. <i>International Journal of Pharmaceutics</i> , 2018, 543, 83-95.	2.6	22
284	Biomimetic synthesis and evaluation of histidine-derivative templated chiral mesoporous silica for improved oral delivery of the poorly water-soluble drug, nimodipine. <i>European Journal of Pharmaceutical Sciences</i> , 2018, 117, 321-330.	1.9	22
285	Animal models of smoke inhalation injury and related acute and chronic lung diseases. <i>Advanced Drug Delivery Reviews</i> , 2018, 123, 107-134.	6.6	22
286	Bulk to Nanometer-Scale Infrared Spectroscopy of Pharmaceutical Dry Powder Aerosols. <i>Analytical Chemistry</i> , 2020, 92, 8323-8332.	3.2	22
287	Inhaled mannitol shifts exhaled nitric oxide in opposite directions in asthmatics and healthy subjects. <i>Respiration Physiology</i> , 2001, 124, 141-150.	2.8	21
288	Particle Aerosolisation and Break-Up in Dry Powder Inhalers: Evaluation and Modelling of Impaction Effects for Agglomerated Systems. <i>Journal of Pharmaceutical Sciences</i> , 2011, 100, 2744-2754.	1.6	21

#	ARTICLE	IF	CITATIONS
289	Lipid Shell-Enveloped Polymeric Nanoparticles with High Integrity of Lipid Shells Improve Mucus Penetration and Interaction with Cystic Fibrosis-Related Bacterial Biofilms. <i>ACS Applied Materials & Interfaces</i> , 2018, 10, 10678-10687.	4.0	21
290	Formulating Inhalable Dry Powders Using Two-Fluid and Three-Fluid Nozzle Spray Drying. <i>Pharmaceutical Research</i> , 2018, 35, 247.	1.7	21
291	Qualitative and quantitative analysis of the biophysical interaction of inhaled nanoparticles with pulmonary surfactant by using quartz crystal microbalance with dissipation monitoring. <i>Journal of Colloid and Interface Science</i> , 2019, 545, 162-171.	5.0	21
292	Multi-breath dry powder inhaler for delivery of cohesive powders in the treatment of bronchiectasis. <i>Drug Development and Industrial Pharmacy</i> , 2015, 41, 859-865.	0.9	20
293	Atomized Human Amniotic Mesenchymal Stromal Cells for Direct Delivery to the Airway for Treatment of Lung Injury. <i>Journal of Aerosol Medicine and Pulmonary Drug Delivery</i> , 2016, 29, 514-524.	0.7	20
294	Tuning Ciprofloxacin Release Profiles from Liposomally Encapsulated Nanocrystalline Drug. <i>Pharmaceutical Research</i> , 2016, 33, 2748-2762.	1.7	20
295	In vivo evaluation of lipid-based formulations for oral delivery of apomorphine and its diester prodrugs. <i>International Journal of Pharmaceutics</i> , 2016, 513, 211-217.	2.6	20
296	Effect of ethanol as a co-solvent on the aerosol performance and stability of spray-dried lysozyme. <i>International Journal of Pharmaceutics</i> , 2016, 513, 175-182.	2.6	20
297	Examining the ability of empirical correlations to predict subject specific <i>in vivo</i> extrathoracic aerosol deposition during tidal breathing. <i>Aerosol Science and Technology</i> , 2017, 51, 363-376.	1.5	20
298	Polyester based nanovehicles for siRNA delivery. <i>Materials Science and Engineering C</i> , 2018, 92, 1006-1015.	3.8	20
299	Erlotinib-loaded carboxymethyl tamarind gum semi-interpenetrating nanocomposites. <i>Carbohydrate Polymers</i> , 2020, 230, 115664.	5.1	20
300	Predicting electrophoretic mobility of beta-blockers in a water-methanol based electrolyte system. <i>Chromatographia</i> , 2003, 57, 191-195.	0.7	19
301	Impact angles as an alternative way to improve aerosolisation of powders for inhalation?. <i>European Journal of Pharmaceutical Sciences</i> , 2010, 41, 320-327.	1.9	19
302	Assessing the combinatorial influence of climate, formulation and device on powder aerosolization using the Taguchi experimental design. <i>Powder Technology</i> , 2012, 226, 253-260.	2.1	19
303	Crystallization of Piroxicam Solid Forms and the Effects of Additives. <i>Chemical Engineering and Technology</i> , 2014, 37, 1297-1304.	0.9	19
304	Investigation of protein distribution in solid lipid particles and its impact on protein release using coherent anti-Stokes Raman scattering microscopy. <i>Journal of Controlled Release</i> , 2015, 197, 111-120.	4.8	19
305	Pulmonary drug delivery to older people. <i>Advanced Drug Delivery Reviews</i> , 2018, 135, 50-61.	6.6	19
306	Cough as an adverse effect on inhalation pharmaceutical products. <i>British Journal of Pharmacology</i> , 2020, 177, 4096-4112.	2.7	19

#	ARTICLE	IF	CITATIONS
307	Solid State Properties of an Oral Iron Chelator, 1,2-Dimethyl-3-hydroxy-4-pyridone, and Its Acetic Acid Solvate. I: Physicochemical Characterization, Intrinsic Dissolution Rate, and Solution Thermodynamics. <i>Journal of Pharmaceutical Sciences</i> , 1991, 80, 677-685.	1.6	18
308	The Contribution of Different Formulation Components on the Aerosol Charge in Carrier-Based Dry Powder Inhaler Systems. <i>Pharmaceutical Research</i> , 2010, 27, 1325-1336.	1.7	18
309	The effect of device resistance and inhalation flow rate on the lung deposition of orally inhaled mannitol dry powder. <i>International Journal of Pharmaceutics</i> , 2016, 513, 294-301.	2.6	18
310	In Vitro Evaluation of Inhalable Verapamil-Rifapentine Particles for Tuberculosis Therapy. <i>Molecular Pharmaceutics</i> , 2016, 13, 979-989.	2.3	18
311	Inhaled antibiotics in the treatment of non-cystic fibrosis bronchiectasis: clinical and drug delivery perspectives. <i>Expert Opinion on Drug Delivery</i> , 2016, 13, 7-22.	2.4	18
312	Protective effect of sodium stearate on the moisture-induced deterioration of hygroscopic spray-dried powders. <i>International Journal of Pharmaceutics</i> , 2018, 541, 11-18.	2.6	18
313	Anti-solvent Precipitation Method Coupled Electrospinning Process to Produce Poorly Water-Soluble Drug-Loaded Orodispersible Films. <i>AAPS PharmSciTech</i> , 2019, 20, 273.	1.5	18
314	Overcoming challenges for development of amorphous powders for inhalation. <i>Expert Opinion on Drug Delivery</i> , 2020, 17, 1583-1595.	2.4	18
315	Optimization of inhalable liposomal powder formulations and evaluation of their in vitro drug delivery behavior in Calu-3 human lung epithelial cells. <i>International Journal of Pharmaceutics</i> , 2020, 586, 119570.	2.6	18
316	Formation of ciprofloxacin nanocrystals within liposomes by spray drying for controlled release via inhalation. <i>International Journal of Pharmaceutics</i> , 2020, 578, 119045.	2.6	18
317	High frequency acoustic nebulization for pulmonary delivery of antibiotic alternatives against <i>Staphylococcus aureus</i> . <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2020, 151, 181-188.	2.0	18
318	The upregulated intestinal folate transporters direct the uptake of ligand-modified nanoparticles for enhanced oral insulin delivery. <i>Acta Pharmaceutica Sinica B</i> , 2022, 12, 1460-1472.	5.7	18
319	Effects of additives on heat denaturation of rhDNase in solutions. <i>Pharmaceutical Research</i> , 1996, 13, 756-761.	1.7	17
320	Use of Aerosols for Bronchial Provocation Testing in the Laboratory: Where We Have Been and Where We Are Going. <i>Journal of Aerosol Medicine and Pulmonary Drug Delivery</i> , 2002, 15, 313-324.	1.2	17
321	Aerosol Performance and Long-Term Stability of Surfactant-Associated Liposomal Ciprofloxacin Formulations with Modified Encapsulation and Release Properties. <i>AAPS PharmSciTech</i> , 2014, 15, 1218-1227.	1.5	17
322	A novel inhaled multi-pronged attack against respiratory bacteria. <i>European Journal of Pharmaceutical Sciences</i> , 2015, 70, 37-44.	1.9	17
323	Novel Budesonide Particles for Dry Powder Inhalation Prepared Using a Microfluidic Reactor Coupled With Ultrasonic Spray Freeze Drying. <i>Journal of Pharmaceutical Sciences</i> , 2017, 106, 1881-1888.	1.6	17
324	Integrated Continuous Plug-Flow Crystallization and Spray Drying of Pharmaceuticals for Dry Powder Inhalation. <i>Industrial & Engineering Chemistry Research</i> , 2019, 58, 16843-16857.	1.8	17

#	ARTICLE	IF	CITATIONS
325	Monoterpenes-containing PEGylated transfersomes for enhancing joint cavity drug delivery evidenced by CLSM and double-sited microdialysis. <i>Materials Science and Engineering C</i> , 2020, 113, 110929.	3.8	17
326	Preparation of NaCl Powder Suitable for Inhalation. <i>Industrial & Engineering Chemistry Research</i> , 2006, 45, 4188-4192.	1.8	16
327	Nanodrug particles and nanoformulations for drug delivery. <i>Advanced Drug Delivery Reviews</i> , 2011, 63, 405.	6.6	16
328	Design of spray dried insulin microparticles to bypass deposition in the extrathoracic region and maximize total lung dose. <i>International Journal of Pharmaceutics</i> , 2016, 511, 1070-1079.	2.6	16
329	Apomorphine and its esters: Differences in Caco-2 cell permeability and chylomicron affinity. <i>International Journal of Pharmaceutics</i> , 2016, 509, 499-506.	2.6	16
330	Novel combination proliposomes containing tobramycin and clarithromycin effective against <i>Pseudomonas aeruginosa</i> biofilms. <i>International Journal of Pharmaceutics</i> , 2018, 552, 130-138.	2.6	16
331	High siRNA loading powder for inhalation prepared by co-spray drying with human serum albumin. <i>International Journal of Pharmaceutics</i> , 2019, 572, 118818.	2.6	16
332	Design of Inhalable Solid Dosage Forms of Budesonide and Theophylline for Pulmonary Combination Therapy. <i>AAPS PharmSciTech</i> , 2019, 20, 137.	1.5	16
333	Does upper airway deformation affect drug deposition?. <i>International Journal of Pharmaceutics</i> , 2019, 572, 118773.	2.6	16
334	Molecular structure and impact of amorphization strategies on intrinsic dissolution of spray dried indomethacin. <i>European Journal of Pharmaceutical Sciences</i> , 2019, 129, 1-9.	1.9	16
335	Inhalable Hydroxychloroquine Powders for Potential Treatment of COVID-19. <i>Journal of Aerosol Medicine and Pulmonary Drug Delivery</i> , 2021, 34, 20-31.	0.7	16
336	A quantitative approach to predicting lung deposition profiles of pharmaceutical powder aerosols. <i>International Journal of Pharmaceutics</i> , 2021, 602, 120568.	2.6	16
337	Rational Development of a Carrier-Free Dry Powder Inhalation Formulation for Respiratory Viral Infections via Quality by Design: A Drug-Drug Cocrystal of Favipiravir and Theophylline. <i>Pharmaceutics</i> , 2022, 14, 300.	2.0	16
338	Methotrexate: Existence of different types of solid. <i>International Journal of Pharmaceutics</i> , 1991, 68, 179-190.	2.6	15
339	Effects of terbutaline in combination with mannitol on mucociliary clearance. <i>European Respiratory Journal</i> , 2002, 20, 1423-1429.	3.1	15
340	Measuring Bipolar Charge and Mass Distributions of Powder Aerosols by a Novel Tool (BOLAR). <i>Molecular Pharmaceutics</i> , 2015, 12, 3433-3440.	2.3	15
341	Inhalation of Respirable Crystalline Rifapentine Particles Induces Pulmonary Inflammation. <i>Molecular Pharmaceutics</i> , 2017, 14, 328-335.	2.3	15
342	The Delivery of High-Dose Dry Powder Antibiotics by a Low-Cost Generic Inhaler. <i>AAPS Journal</i> , 2017, 19, 191-202.	2.2	15

#	ARTICLE	IF	CITATIONS
343	Effect of excipients on encapsulation and release of insulin from spray-dried solid lipid microparticles. <i>International Journal of Pharmaceutics</i> , 2018, 550, 439-446.	2.6	15
344	Stability of lysozyme incorporated into electrospun fibrous mats for wound healing. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2019, 136, 240-249.	2.0	15
345	Hydrogel formulations containing non-ionic polymers for topical delivery of bacteriophages. <i>International Journal of Pharmaceutics</i> , 2021, 605, 120850.	2.6	15
346	Phage Therapy for Multi-Drug Resistant Respiratory Tract Infections. <i>Viruses</i> , 2021, 13, 1809.	1.5	15
347	Lipid nanoparticles for the inhalation of mRNA. <i>Nature Biomedical Engineering</i> , 2021, 5, 949-950.	11.6	15
348	Dissolution Kinetic Behavior of Drug Nanoparticles and their Conformity to the Diffusion Model. <i>Langmuir</i> , 2008, 24, 7538-7544.	1.6	14
349	Steroid-Decorated Antibiotic Microparticles for Inhaled Anti-Infective Therapy. <i>Journal of Pharmaceutical Sciences</i> , 2014, 103, 1115-1125.	1.6	14
350	Murine pharmacokinetics of rifapentine delivered as an inhalable dry powder. <i>International Journal of Antimicrobial Agents</i> , 2015, 45, 319-323.	1.1	14
351	Understanding the Different Effects of Inhaler Design on the Aerosol Performance of Drug-Only and Carrier-Based DPI Formulations. Part 1: Grid Structure. <i>AAPS Journal</i> , 2016, 18, 1159-1167.	2.2	14
352	Efficacy of oral lipid-based formulations of apomorphine and its diester in a Parkinson's disease rat model. <i>Journal of Pharmacy and Pharmacology</i> , 2017, 69, 1110-1115.	1.2	14
353	Pulmonary Pharmacokinetics of Colistin following Administration of Dry Powder Aerosols in Rats. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	1.4	14
354	Understanding the Impacts of Surface Compositions on the In-Vitro Dissolution and Aerosolization of Co-Spray-Dried Composite Powder Formulations for Inhalation. <i>Pharmaceutical Research</i> , 2019, 36, 6.	1.7	14
355	Polymeric Nanocarriers With Mucus-Diffusive and Mucus-Adhesive Properties to Control Pharmacokinetic Behavior of Orally Dosed Cyclosporine A. <i>Journal of Pharmaceutical Sciences</i> , 2020, 109, 1079-1085.	1.6	14
356	Storage stability of phage-ciprofloxacin combination powders against <i>Pseudomonas aeruginosa</i> respiratory infections. <i>International Journal of Pharmaceutics</i> , 2020, 591, 119952.	2.6	14
357	Potential effects of lingual fats on airway flow dynamics and particle deposition. <i>Aerosol Science and Technology</i> , 2020, 54, 321-331.	1.5	14
358	The effects of different doses of inhaled bacteriophage therapy for <i>Pseudomonas aeruginosa</i> pulmonary infections in mice. <i>Clinical Microbiology and Infection</i> , 2022, 28, 983-989.	2.8	14
359	Development of a mathematical model for the water distribution in freeze-dried solids. <i>Pharmaceutical Research</i> , 1999, 16, 660-665.	1.7	13
360	Mannitol Delivery by Vibrating Mesh Nebulisation for Enhancing Mucociliary Clearance. <i>Journal of Pharmaceutical Sciences</i> , 2011, 100, 2693-2702.	1.6	13

#	ARTICLE	IF	CITATIONS
361	NanoXCT: A Novel Technique to Probe the Internal Architecture of Pharmaceutical Particles. <i>Pharmaceutical Research</i> , 2014, 31, 3085-3094.	1.7	13
362	The future perspectives of natural materials for pulmonary drug delivery and lung tissue engineering. <i>Expert Opinion on Drug Delivery</i> , 2015, 12, 869-887.	2.4	13
363	The effects of upper airway tissue motion on airflow dynamics. <i>Journal of Biomechanics</i> , 2020, 99, 109506.	0.9	13
364	In silico design and 3D printing of microfluidic chips for the preparation of size-controllable siRNA nanocomplexes. <i>International Journal of Pharmaceutics</i> , 2020, 583, 119388.	2.6	13
365	Storage stability of inhalable, controlled-release powder formulations of ciprofloxacin nanocrystal-containing liposomes. <i>International Journal of Pharmaceutics</i> , 2021, 605, 120809.	2.6	13
366	In vitro-in vivo correlation of cascade impactor data for orally inhaled pharmaceutical aerosols. <i>Advanced Drug Delivery Reviews</i> , 2021, 177, 113952.	6.6	13
367	Pharmacokinetics and pharmacodynamics of peptide antibiotics. <i>Advanced Drug Delivery Reviews</i> , 2022, 183, 114171.	6.6	13
368	Electrostatics of pharmaceutical inhalation aerosols. <i>Journal of Pharmacy and Pharmacology</i> , 2009, 61, 1587-1599.	1.2	13
369	The effect of spacers on the delivery of metered dose aerosols of nedocromil sodium and disodium cromoglycate. <i>International Journal of Pharmaceutics</i> , 2000, 200, 87-91.	2.6	12
370	Delivery of High Solubility Polyols by Vibrating Mesh Nebulizer to Enhance Mucociliary Clearance. <i>Journal of Aerosol Medicine and Pulmonary Drug Delivery</i> , 2012, 25, 297-305.	0.7	12
371	High speed imaging with electrostatic charge monitoring to track powder deagglomeration upon impact. <i>Journal of Aerosol Science</i> , 2013, 65, 77-87.	1.8	12
372	In vitro evaluation of novel inhalable dry powders consisting of thioridazine and rifapentine for rapid tuberculosis treatment. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2016, 107, 205-214.	2.0	12
373	New nano-matrix oral formulation of nanoprecipitated cyclosporine A prepared with multi-inlet vortex mixer. <i>International Journal of Pharmaceutics</i> , 2017, 516, 116-119.	2.6	12
374	Mechanism-Based Pharmacokinetic/Pharmacodynamic Modeling of Aerosolized Colistin in a Mouse Lung Infection Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	1.4	12
375	High Resolution Nanoscale Probing of Bacteriophages in an Inhalable Dry Powder Formulation for Pulmonary Infections. <i>Analytical Chemistry</i> , 2019, 91, 12760-12767.	3.2	12
376	Nanoscale Probing of Liposome Encapsulating Drug Nanocrystal Using Atomic Force Microscopy-Infrared Spectroscopy. <i>Analytical Chemistry</i> , 2020, 92, 9922-9931.	3.2	12
377	Integrated Continuous Crystallization and Spray Drying of Insulin for Pulmonary Drug Delivery. <i>Crystal Growth and Design</i> , 2021, 21, 501-511.	1.4	12
378	Calculation of electrophoretic mobility in mixed solvent buffers in capillary zone electrophoresis using a mixture response surface method. <i>Analyst</i> , The, 2002, 127, 1188-1192.	1.7	11

#	ARTICLE	IF	CITATIONS
379	Mathematical representation of electrophoretic mobility of basic drugs in ternary solvent buffers in capillary zone electrophoresis. <i>Journal of Chromatography A</i> , 2003, 994, 191-198.	1.8	11
380	Lack of a synergistic effect of arginine-glutamic acid on the physical stability of spray-dried bovine serum albumin. <i>Pharmaceutical Development and Technology</i> , 2017, 22, 785-791.	1.1	11
381	Investigation of nanocarriers and excipients for preparation of nanoembedded microparticles. <i>International Journal of Pharmaceutics</i> , 2017, 526, 300-308.	2.6	11
382	Elucidating the Pharmacokinetics/Pharmacodynamics of Aerosolized Colistin against Multidrug-Resistant <i>Acinetobacter baumannii</i> and <i>Klebsiella pneumoniae</i> in a Mouse Lung Infection Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	1.4	11
383	A new hypothesis to investigate bioequivalence of pharmaceutical inhalation products. <i>DARU, Journal of Pharmaceutical Sciences</i> , 2019, 27, 517-524.	0.9	11
384	Spray drying lactose from organic solvent suspensions for aerosol delivery to the lungs. <i>International Journal of Pharmaceutics</i> , 2020, 591, 119984.	2.6	11
385	Nebulised Isotonic Hydroxychloroquine Aerosols for Potential Treatment of COVID-19. <i>Pharmaceutics</i> , 2021, 13, 1260.	2.0	11
386	Current Advances and Future Trends in Characterizing Poorly Water-soluble Drugs Using Spectroscopic, Imaging and Data Analytical Techniques. <i>Current Pharmaceutical Design</i> , 2014, 20, 436-453.	0.9	11
387	Recent Applications of Supercritical Fluid Technology to Pharmaceutical Powder Systems. <i>KONA Powder and Particle Journal</i> , 2001, 19, 57-70.	0.9	10
388	The Influence of Actuator Materials and Nozzle Designs on Electrostatic Charge of Pressurised Metered Dose Inhaler (pMDI) Formulations. <i>Pharmaceutical Research</i> , 2014, 31, 1325-1337.	1.7	10
389	Applicability of Bipolar Charge Analyzer (BOLAR) in Characterizing the Bipolar Electrostatic Charge Profile of Commercial Metered Dose Inhalers (MDIs). <i>Pharmaceutical Research</i> , 2016, 33, 283-291.	1.7	10
390	Powder aerosol delivery through nasal high-flow system: In vitro feasibility and influence of process conditions. <i>International Journal of Pharmaceutics</i> , 2017, 533, 187-197.	2.6	10
391	Improved prediction of intersubject variability in extrathoracic aerosol deposition using algebraic correlations. <i>Aerosol Science and Technology</i> , 2017, 51, 667-673.	1.5	10
392	The inhibitory effects of eighteen front-line antibiotics on the substrate uptake mediated by human Organic anion/cation transporters, Organic anion transporting polypeptides and Oligopeptide transporters in in vitro models. <i>European Journal of Pharmaceutical Sciences</i> , 2018, 115, 132-143.	1.9	10
393	Poly(ethylene carbonate)-containing polylactic acid microparticles with rifampicin improve drug delivery to macrophages. <i>Journal of Pharmacy and Pharmacology</i> , 2018, 70, 1009-1021.	1.2	10
394	Studies of Radioaerosol Deposition in the Respiratory Tract. <i>Seminars in Nuclear Medicine</i> , 2019, 49, 62-70.	2.5	10
395	Synergistic antibacterial effect of inhaled aztreonam and tobramycin fixed dose combination to combat multidrug-resistant Gram-negative bacteria. <i>International Journal of Pharmaceutics</i> , 2020, 590, 119877.	2.6	10
396	Comparative assessment of in vitro/in vivo performances of orodispersible electrospun and casting films containing rizatriptan benzoate. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2020, 154, 283-289.	2.0	10

#	ARTICLE	IF	CITATIONS
397	Effects of the Glass-Forming Ability and Annealing Conditions on Cocrystallization Behaviors via Rapid Solvent Removal: A Case Study of Voriconazole. <i>Pharmaceutics</i> , 2020, 12, 1209.	2.0	10
398	Effect of Relative Humidity on Bipolar Electrostatic Charge Profiles of dry Powder Aerosols. <i>Pharmaceutical Research</i> , 2017, 34, 1707-1715.	1.7	10
399	Combination and nanotechnology based pharmaceutical strategies for combating respiratory bacterial biofilm infections. <i>International Journal of Pharmaceutics</i> , 2022, 616, 121507.	2.6	10
400	Serendipitous preparation of crystals of methotrexate and attempts to modify its crystal habit. <i>Journal of Crystal Growth</i> , 1989, 94, 488-498.	0.7	9
401	Crystal Structures of a New Oral Iron Chelator, 1,2-Dimethyl-3-hydroxy-4- pyridone, and its Solvates with Acetic Acid and Formic Acid. <i>Journal of Pharmaceutical Sciences</i> , 1992, 81, 353-358.	1.6	9
402	Pulmonary Delivery of Peptides and Proteins. , 2011, , 23-46.		9
403	The effect of lactose micro-spherical crystals prepared by conditioning with supercritical fluid on salbutamol sulphate inhalation performance. <i>Journal of Supercritical Fluids</i> , 2012, 71, 92-101.	1.6	9
404	The production of dry powder by the sonocrystallisation for inhalation drug delivery. <i>Powder Technology</i> , 2013, 246, 337-344.	2.1	9
405	Attachment of micro- and nano-particles on tipless cantilevers for colloidal probe microscopy. <i>Journal of Colloid and Interface Science</i> , 2014, 426, 190-198.	5.0	9
406	Biopharmaceutical Evaluation of Novel Cyclosporine A Nano-matrix Particles for Inhalation. <i>Pharmaceutical Research</i> , 2016, 33, 2107-2116.	1.7	9
407	Development of an Improved Inhalable Powder Formulation of Pirfenidone by Spray-Drying: In Vitro Characterization and Pharmacokinetic Profiling. <i>Pharmaceutical Research</i> , 2016, 33, 1447-1455.	1.7	9
408	Investigation of factors affecting the stability of lysozyme spray dried from ethanol-water solutions. <i>International Journal of Pharmaceutics</i> , 2017, 534, 263-271.	2.6	9
409	In vivo evaluation of solid lipid microparticles and hybrid polymer-lipid microparticles for sustained delivery of leuprolide. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2019, 142, 315-321.	2.0	9
410	Gastrointestinal Responsive Polymeric Nanoparticles for Oral Delivery of Insulin: Optimized Preparation, Characterization, and In Vivo Evaluation. <i>Journal of Pharmaceutical Sciences</i> , 2019, 108, 2994-3002.	1.6	9
411	In vivo deposition study of a new generation nebuliser utilising hybrid resonant acoustic (HYDRA) technology. <i>International Journal of Pharmaceutics</i> , 2020, 580, 119196.	2.6	9
412	Enteric-coated bacteriophage tablets for oral administration against gastrointestinal infections. <i>International Journal of Pharmaceutics</i> , 2021, 609, 121206.	2.6	9
413	Transformation of nanoparticles into compacts: A study on PLGA and celecoxib nanoparticles. <i>International Journal of Pharmaceutics</i> , 2022, 611, 121278.	2.6	9
414	Hexamethylmelamine: a study of solvation and crystallisation. <i>Journal of the Chemical Society Perkin Transactions II</i> , 1987, , 1747.	0.9	8

#	ARTICLE	IF	CITATIONS
415	Recent advances in understanding the influence of composite-formulation properties on the performance of dry powder inhalers. <i>Physica B: Condensed Matter</i> , 2007, 394, 315-319.	1.3	8
416	Validation of computation method to predict aerodynamic diameter of particles with rough surface. <i>Powder Technology</i> , 2009, 192, 74-84.	2.1	8
417	Computational fluid dynamics (CFD) investigation of the gas–solid flow and performance of Andersen cascade impactor. <i>Powder Technology</i> , 2015, 285, 128-137.	2.1	8
418	A Proof-of-Principle Setup for Delivery of Relenza [®] (Zanamivir) Inhalation Powder to Intubated Patients. <i>Journal of Aerosol Medicine and Pulmonary Drug Delivery</i> , 2016, 29, 30-35.	0.7	8
419	Effect of Spacers on the Bipolar Electrostatic Charge Properties of Metered Dose Inhaler Aerosols—A Case Study With Tilade [®] . <i>Journal of Pharmaceutical Sciences</i> , 2017, 106, 1553-1559.	1.6	8
420	Insight into Nanoscale Network of Spray-Dried Polymeric Particles: Role of Polymer Molecular Conformation. <i>ACS Applied Materials & Interfaces</i> , 2018, 10, 36686-36692.	4.0	8
421	Mesoporous silicas templated by heterocyclic amino acid derivatives: Biomimetic synthesis and drug release application. <i>Materials Science and Engineering C</i> , 2018, 93, 407-418.	3.8	8
422	Aerosol drug delivery to the lungs during nasal high flow therapy: an in vitro study. <i>BMC Pulmonary Medicine</i> , 2019, 19, 42.	0.8	8
423	Treatment of infections caused by Gram-negative pathogens: current status on the pharmacokinetics/pharmacodynamics of parenteral and inhaled polymyxins in patients. <i>International Journal of Antimicrobial Agents</i> , 2020, 56, 106199.	1.1	8
424	Can bacteriophage endolysins be nebulised for inhalation delivery against <i>Streptococcus pneumoniae</i> ?. <i>International Journal of Pharmaceutics</i> , 2020, 591, 119982.	2.6	8
425	Enhancing Stability and Tooth Bleaching Activity of Carbamide Peroxide by Electrospun Nanofibrous Film. <i>Pharmaceutics</i> , 2020, 13, 381.	1.7	8
426	Predicting the composition and size distribution of dry particles for aerosols and sprays of suspension: A Monte Carlo approach. <i>International Journal of Pharmaceutics</i> , 2020, 582, 119311.	2.6	8
427	Synthesis and Radiolabelling of Ipratropium and Tiotropium for Use as PET Ligands in the Study of Inhaled Drug Deposition. <i>Australian Journal of Chemistry</i> , 2006, 59, 53.	0.5	7
428	Development of an In Vivo Ovine Dry Powder Inhalation Model for the Evaluation of Conventional and Controlled Release Microparticles. <i>AAPS Journal</i> , 2009, 11, 465-8.	2.2	7
429	A Novel In-Line Delivery System to Administer Dry Powder Mannitol to Mechanically Ventilated Patients. <i>Journal of Aerosol Medicine and Pulmonary Drug Delivery</i> , 2017, 30, 100-107.	0.7	7
430	A research pathway for the study of the delivery and disposition of nebulised antibiotics: an incremental approach from in vitro to large animal models. <i>Intensive Care Medicine Experimental</i> , 2018, 6, 17.	0.9	7
431	A dual action of D-amino acids on anti-biofilm activity and moisture-protection of inhalable ciprofloxacin powders. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2022, 173, 132-140.	2.0	7
432	Mathematical representation of electrophoretic mobility in mixed aqueous-methanolic buffers in capillary zone electrophoresis. <i>Journal of Separation Science</i> , 2001, 13, 346-350.	1.0	6

#	ARTICLE	IF	CITATIONS
433	Effect of Mouthpiece Washing on Aerosol Performance of CFC-Free Ventolin [®] . <i>Journal of Asthma</i> , 2004, 41, 721-727.	0.9	6
434	Pulmonary drug delivery. <i>Therapeutic Delivery</i> , 2013, 4, 877-878.	1.2	6
435	Predicting physical stability in pressurized metered dose inhalers via dwell and instantaneous force colloidal probe microscopy. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2014, 88, 129-135.	2.0	6
436	Bipolar electrostatic charge and mass distributions of powder aerosols—Effects of inhaler design and inhaler material. <i>Journal of Aerosol Science</i> , 2016, 95, 104-117.	1.8	6
437	Concentration profile of tobramycin in exhaled breath condensate after inhalation of a single dose: A pilot study. <i>Journal of Drug Delivery Science and Technology</i> , 2021, 62, 102394.	1.4	6
438	Co-spray dried hydrophobic drug formulations with crystalline lactose for inhalation aerosol delivery. <i>International Journal of Pharmaceutics</i> , 2021, 602, 120608.	2.6	6
439	Effect of inflow conditioning for dry powder inhalers. <i>International Journal of Pharmaceutics</i> , 2021, 608, 121085.	2.6	6
440	Raman spectroscopic evaluation of crystallinity, chemical composition and stability of pharmaceutical powder aerosols. <i>International Journal of Pharmaceutics</i> , 2021, 611, 121341.	2.6	6
441	Inhaled Delivery of Anti-Pseudomonas Phages to Tackle Respiratory Infections Caused by Superbugs. <i>Journal of Aerosol Medicine and Pulmonary Drug Delivery</i> , 2022, 35, 73-82.	0.7	6
442	Studies of the mechanism of crystal growth of hexamethylmelamine. <i>Journal of Crystal Growth</i> , 1990, 104, 355-364.	0.7	5
443	Calculation of electrophoretic mobility in ternary solvent electrolyte systems. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2003, 32, 203-208.	1.4	5
444	The Effect of Active Pharmaceutical Ingredients on Aerosol Electrostatic Charges from Pressurized Metered Dose Inhalers. <i>Pharmaceutical Research</i> , 2015, 32, 2928-2936.	1.7	5
445	Improved antibacterial efficiency of inhaled thiamphenicol dry powders: Mathematical modelling of in vitro dissolution kinetic and in vitro antibacterial efficacy. <i>European Journal of Pharmaceutical Sciences</i> , 2020, 152, 105435.	1.9	5
446	A Review of Methods for Evaluating Particle Stability in Suspension Based Pressurized Metered Dose Inhalers. <i>Current Pharmaceutical Design</i> , 2015, 21, 3955-3965.	0.9	5
447	In-Vitro Characterization and Oral Bioavailability of Organic Solvent-free Solid Dispersions Containing Telmisartan. <i>Iranian Journal of Pharmaceutical Research</i> , 2016, 15, 385-94.	0.3	5
448	From laminar to turbulent flow in a dry powder inhaler: The effect of simple design modifications. <i>International Journal of Pharmaceutics</i> , 2022, 616, 121556.	2.6	5
449	Evaluating the pharmacokinetics of intrapulmonary administered ciprofloxacin solution for respiratory infections using in vivo and in silico PBPK rat model studies. <i>Chinese Chemical Letters</i> , 2023, 34, 107463.	4.8	5
450	Pharmaceutical Dry Powder Aerosol Delivery. <i>KONA Powder and Particle Journal</i> , 2001, 19, 46-56.	0.9	4

#	ARTICLE	IF	CITATIONS
451	Comparison of different algorithms to calculate electrophoretic mobility of analytes as a function of binary solvent composition. <i>Electrophoresis</i> , 2003, 24, 1596-1602.	1.3	4
452	CFD analysis of the aerosolization of carrier-based dry powder inhaler formulations. , 2013, , .		4
453	Isothermal Microcalorimetry of Pressurized Systems I: A Rapid Method to Evaluate Pressurized Metered Dose Inhaler Formulations. <i>Pharmaceutical Research</i> , 2014, 31, 2716-2723.	1.7	4
454	The Effect of Actuator Nozzle Designs on the Electrostatic Charge Generated in Pressurised Metered Dose Inhaler Aerosols. <i>Pharmaceutical Research</i> , 2015, 32, 1237-1248.	1.7	4
455	Characterisation of 40â€­mg/ml and 100â€­mg/ml tobramycin formulations for aerosol therapy with adult mechanical ventilation. <i>Pulmonary Pharmacology and Therapeutics</i> , 2018, 50, 93-99.	1.1	4
456	Inhaled non-steroidal polyphenolic alternatives for anti-inflammatory combination therapy. <i>Powder Technology</i> , 2018, 339, 244-255.	2.1	4
457	Surface Composition and Aerosolization Stability of an Inhalable Combinational Powder Formulation Spray Dried Using a Three-Fluid Nozzle. <i>Pharmaceutical Research</i> , 2020, 37, 219.	1.7	4
458	Administration of dry powders during respiratory supports. <i>Annals of Translational Medicine</i> , 2021, 9, 596-596.	0.7	4
459	Pharmacokinetics and safety of inhaled ivermectin in mice as a potential COVID-19 treatment. <i>International Journal of Pharmaceutics</i> , 2022, 619, 121688.	2.6	4
460	Topical liquid formulation of bacteriophages for metered-dose spray delivery. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2022, 177, 1-8.	2.0	4
461	Dissolution studies of hexamethylmelamine. <i>International Journal of Pharmaceutics</i> , 1993, 95, 143-151.	2.6	3
462	Preparation of Radiolabeled Materials for Studies of Deposition of Fibers in the Human Respiratory Tract. <i>Journal of Aerosol Medicine and Pulmonary Drug Delivery</i> , 1993, 6, 241-249.	1.2	3
463	The impact of particle preparation methods and polymorphic stability of lipid excipients on protein distribution in microparticles. <i>Drug Development and Industrial Pharmacy</i> , 2017, 43, 2032-2042.	0.9	3
464	Influence of solvent mixtures on HPMCAS-celecoxib microparticles prepared by electrospraying. <i>Asian Journal of Pharmaceutical Sciences</i> , 2018, 13, 584-591.	4.3	3
465	Polymyxin-Induced Metabolic Perturbations in Human Lung Epithelial Cells. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, e0083521.	1.4	3
466	Effects of respiratory rate on the fluid mechanics of a reconstructed upper airway. <i>Medical Engineering and Physics</i> , 2022, 100, 103746.	0.8	3
467	Preparation and Characterization of Inhalable Ivermectin Powders as a Potential COVID-19 Therapy. <i>Journal of Aerosol Medicine and Pulmonary Drug Delivery</i> , 2022, , .	0.7	3
468	Studies of the mechanism of crystal growth of hexamethylmelamine II. Rates of growth of the crystal faces. <i>Journal of Crystal Growth</i> , 1991, 108, 751-758.	0.7	2

#	ARTICLE	IF	CITATIONS
469	Formulating Biomolecules: Mechanistic Insights in Molecular Interactions. <i>Advanced Drug Delivery Reviews</i> , 2011, 63, 1051-1052.	6.6	2
470	Safety Of Administering Dry Powder Mannitol To Stimulate Sputum Clearance In Intubated Intensive Care Patients With Sputum Retention: A Pilot Study. , 2012, , .		2
471	Unitary hormonal models, peripheral markers, and evaluation of response to drug: A response to Weisman and Feldman. <i>Psychoneuroendocrinology</i> , 2013, 38, 627-628.	1.3	2
472	Isothermal Microcalorimetry of Pressurized Systems II: Effect of Excipient and Water Ingress on Formulation Stability of Amorphous Glycopyrrolate. <i>Pharmaceutical Research</i> , 2015, 32, 714-722.	1.7	2
473	An Apparatus to Deliver Mannitol Powder for Bronchial Provocation in Children Under Six Years Old. <i>Journal of Aerosol Medicine and Pulmonary Drug Delivery</i> , 2015, 28, 452-461.	0.7	2
474	Monitoring the Inhalation Flow Rate of Nebulized Aerosols Using an Ultrasonic Flow Meter: In Vitro Assessment. <i>Journal of Aerosol Medicine and Pulmonary Drug Delivery</i> , 2017, 30, 173-181.	0.7	2
475	Overcoming Poor Tabletability of Bulky Absorption Enhancers by Spray Drying Technology. <i>Journal of Pharmaceutical Sciences</i> , 2019, 108, 2128-2135.	1.6	2
476	Spray-Dried Particles of Nitric Oxide-Modified Glutathione for the Treatment of Chronic Lung Infection. <i>Molecular Pharmaceutics</i> , 2019, 16, 1723-1731.	2.3	2
477	Generation and characterization of electrostatically charged radiolabelled aerosols for lung scintigraphy. <i>Aerosol Science and Technology</i> , 2021, 55, 640-652.	1.5	2
478	Airway Hyperresponsiveness to Bronchial Mannitol. <i>Chest</i> , 2004, 126, 319-320.	0.4	1
479	Synergistic combination dry powders for inhaled antimicrobial therapy. , 2013, , .		1
480	Quantitative and Qualitative Examination of Particle-particle Interactions Using Colloidal Probe Nanoscopy. <i>Journal of Visualized Experiments</i> , 2014, , .	0.2	1
481	Multiscale Computational Models for Respiratory Aerosol Dynamics with Medical Applications. <i>Computational and Mathematical Methods in Medicine</i> , 2019, 2019, 1-2.	0.7	1
482	How can the challenges faced by nanoparticle-based pulmonary drug formulations be overcome. <i>Therapeutic Delivery</i> , 2019, 10, 87-89.	1.2	1
483	Controlled release antibiotics for dry powder lung delivery. <i>Drug Development and Industrial Pharmacy</i> , 2009, 00, 090805050810080-8.	0.9	1
484	Formulation Challenges. , 2008, , 623-636.		1
485	Crystal structure of aqua(2-[[2-([2-bis(carboxylato- O^{18} -methyl)amino- N^{15}]ethyl)(carboxylato- O^{18} -methyl)amino- N^{15}]ethyl)(carboxymethyl)azaniumyl]acetato)trihydrate. <i>Acta Crystallographica Section E: Crystallographic Communications</i> , 2018, 74, 1054-1057.	1.1	1
486	Numerical Study of Effects of Powder Size and Polydispersity on the Dispersion of Fine Powders in a Cyclonic Flow. , 2009, , .		0

#	ARTICLE	IF	CITATIONS
487	Visualizing powder de-agglomeration upon impact with simultaneous flowing charge behaviour. , 2013, , .		0
488	Editorial (Thematic Issue: Emerging Formulation Design and Drug Delivery Systems for Inhaled) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 70	0.9	0
489	Inhaled antimicrobial chemotherapy for respiratory tract infections: successes, challenges and the road ahead. Advanced Drug Delivery Reviews, 2015, 85, v-vii.	6.6	0
490	In Vitro/In Vivo Comparisons in Pulmonary Drug Delivery. Journal of Aerosol Medicine and Pulmonary Drug Delivery, 2008, .	1.2	0
491	Excipients: Powders and Solid Dosage Forms. , 0, , 3350-3359.		0
492	Pulmonary Delivery of Antibiotics for Respiratory Infections. , 2016, , 131-150.		0
493	Inhaled Therapeutic siRNA for the Treatment of Respiratory Diseases. , 2016, , 31-48.		0
494	Solid State Testing of Inhaled Formulations. , 2019, , 523-540.		0
495	Microextraction and Chromatographic Analysis of Budesonide Epimers in Exhaled Breath Condensate. Current Analytical Chemistry, 2020, 16, 1032-1040.	0.6	0
496	Polymyxin Induces Significant Transcriptomic Perturbations of Cellular Signalling Networks in Human Lung Epithelial Cells. Antibiotics, 2022, 11, 307.	1.5	0